Psychedelics review advanced after Joe Rogan text to Trump.

President Trump signed an executive order directing federal agencies to fast-track research and regulatory review of psychedelic drugs after a private text exchange with podcast host Joe Rogan, the administration said. The directive asks the FDA to expedite breakthrough therapy designations and encourages interagency data sharing.

President Donald Trump signed an executive order directing federal agencies to accelerate research and regulatory review of psychedelic drugs after a private text exchange with podcast host Joe Rogan. The order asks the Food and Drug Administration to expedite breakthrough therapy designations, encourages data sharing across agencies, and creates a pathway for faster scheduling changes if safety and efficacy are demonstrated. Administration officials said the action followed months of internal discussions led by Health and Human Services Secretary Robert F. Kennedy Jr., and that the outreach from Rogan helped speed the timeline. Officials framed the move as part of broader efforts to address mental health, addiction, and veteran care. Known details: - The executive order targets substances including ibogaine and LSD, which remain classified as Schedule I drugs under federal law. - The directive asks the FDA to fast-track breakthrough therapy reviews, promotes interagency data sharing, and opens the possibility of rapid rescheduling if clinical evidence supports it. - Administration officials described the decision as the result of months of work inside the Department of Health and Human Services, with the private text from Joe Rogan reported as an accelerating factor. - Medical experts cited in coverage warn of risks for some compounds; ibogaine has been linked in medical literature to cardiotoxicity and more than 30 deaths. - No psychedelic compound has yet received FDA approval, though psilocybin and MDMA are in clinical trials and some states have legalized supervised psilocybin therapy programs. Summary: The executive order may speed federal research and regulatory review of several psychedelic compounds, with officials highlighting potential benefits for people with severe mental illness, PTSD and addiction. Undetermined at this time is how quickly formal approvals or scheduling changes would occur, and clinical safety and efficacy evaluations remain central to the process.